Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or 'African eye worm,' according to a study published in Clinical Infectious Diseases.
Researchers at the LSTM's Centre for Drugs and Diagnostics, and University of Buea, Cameroon have developed new models of the tropical eye worm, Loa loa for the development of new drugs against filariasis.
Researchers from Case Western Reserve University School of Medicine have shown that a single "cocktail" of three pill-based anti-parasite medications is significantly more effective at killing microscopic larval worms in people diagnosed with lymphatic filariasis, commonly known as elephantiasis, than other standard two-drug combinations previously used in the global effort to eliminate this infectious disease.
Ivermectin is six times more toxic than Moxidectin for insects in charge of the recycling of organic matter. For the first time ever, there is scientific evidence based on physiological studies and this should be taken into account when using antiparasitic agents for livestock.
Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 million people worldwide.
The Berkeley researchers figured out that they could quickly determine who has the Loa loa worm using a smartphone, customized to work like a microscope. They could then skip the medication for those people and give it to everyone else. Kamgno, who received the latest version of the phones in 2016, dubbed the mobile microscopes "revolutionary."
Researchers from the Liverpool School of Tropical Medicine have shown the large potential impact of a completely new type of antimalarial drug that kills mosquitoes, as opposed to existing drugs that target the parasite, to reduce the spread of malaria.
UT Southwestern Medical Center researchers have identified a chemical that suppresses the lethal form of a parasitic infection caused by roundworms that affects up to 100 million people and usually causes only mild symptoms.
River blindness, or onchocerciasis, is a disease caused by a parasitic worm found primarily in Africa. The worm (Onchocerca volvulus) is transmitted to humans as immature larvae through bites of infected black flies.
Osaka Researchers, in partnership with other Japanese and U.S. scientists, report a new gene target, KPNB1, for treatment against epithelial ovarian cancer (EOC).
Malaria affects hundreds of millions of people every year, killing more than half a million. Part of the difficulty of eliminating malaria stems from the fact that a large portion of the at-risk population lives in rural areas where access to doctors can be a challenge.
Research teams from the National Institutes of Health and abroad have identified the first inhibitor of an enzyme long thought to be a potential drug target for fighting disease-causing parasites and bacteria.
The parasite that causes river blindness infects about 37 million people in parts of Africa and Latin America, causing blindness and other major eye and skin diseases in about 5 million of them.
Scientists have sequenced the genome of the parasitic worm responsible for causing onchocerciasis--an eye and skin infection more commonly known as river blindness.
People infected with a parasitic worm called Wuchereria bancrofti in areas where HIV is endemic may be more likely to acquire HIV than people who are not infected with the worm, according to a new study in southwest Tanzania, published in The Lancet.
Two interconnected brain areas - the hippocampus and the entorhinal cortex - help us to know where we are and to remember it later.
PATH and Standard Diagnostics/Alere announced today the commercial availability of two rapid diagnostic tools for onchocerciasis and lymphatic filariasis. Designed for use in disease surveillance, the antibody-based tests are part of a suite of diagnostic innovations intended to support the elimination of neglected tropical diseases (NTDs), a group of illnesses that affect more than a billion people worldwide.
Many of the drugs we use in hospitals – antibiotics, antifungals and anti-cancer drugs, to name but a few – are produced by bacteria that live in the soil beneath our feet.
The world's first vaccine for a disease that causes misery for millions in Africa could be tested within five years.
New Smartphone technology has been developed that can detect and count wriggling parasitic worms in a drop of blood...